| Mayra Pacheco, CRNA | |
|
Urb. El Madrigal, Calle 4 E 24, Ponce, PR 00730-1412 | |
| (787) 901-3343 | |
| Not Available |
| Full Name | Mayra Pacheco |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 4 Years |
| Location | Urb. El Madrigal, Ponce, Puerto Rico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275200180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 135759 (Puerto Rico) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morton Plant Mease Healthcare Countryside | Safety harbor, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greater Florida Anesthesiologists Llc | 3173711017 | 455 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
Doctors have been impressed with the rapid recovery rates instigated by the ‘tailor-made ' discs, which have been devised by a research team at the Sheffield company, CellTran, with financial support from the Wellcome Trust biomedical research charity and the White Rose Technology Seedcorn Fund. They will be officially launched at the British Burn Association's annual meeting in Manchester tomorrow (28th).
Today, Dutch biomedical big data company GENALICE officially launched its all-in-one appliance for Next-Gen Sequencing (NGS) data processing, the GENALICE VAULT, at the annual conference of the American Society of Human Genetics.
About 5.7 million Americans have heart failure, half of whom will die from the disease within 5 years, according to the Centers for Disease Control and Prevention.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.
› Verified 2 days ago
| Entity Name | Greater Florida Anesthesiologists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528630795 PECOS PAC ID: 3173711017 Enrollment ID: O20101220000829 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
Doctors have been impressed with the rapid recovery rates instigated by the ‘tailor-made ' discs, which have been devised by a research team at the Sheffield company, CellTran, with financial support from the Wellcome Trust biomedical research charity and the White Rose Technology Seedcorn Fund. They will be officially launched at the British Burn Association's annual meeting in Manchester tomorrow (28th).
Today, Dutch biomedical big data company GENALICE officially launched its all-in-one appliance for Next-Gen Sequencing (NGS) data processing, the GENALICE VAULT, at the annual conference of the American Society of Human Genetics.
About 5.7 million Americans have heart failure, half of whom will die from the disease within 5 years, according to the Centers for Disease Control and Prevention.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mayra Pacheco, CRNA Urb. El Madrigal, Calle 4 E 24, Ponce, PR 00730-1412 Ph: (787) 901-3343 | Mayra Pacheco, CRNA Urb. El Madrigal, Calle 4 E 24, Ponce, PR 00730-1412 Ph: (787) 901-3343 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
Doctors have been impressed with the rapid recovery rates instigated by the ‘tailor-made ' discs, which have been devised by a research team at the Sheffield company, CellTran, with financial support from the Wellcome Trust biomedical research charity and the White Rose Technology Seedcorn Fund. They will be officially launched at the British Burn Association's annual meeting in Manchester tomorrow (28th).
Today, Dutch biomedical big data company GENALICE officially launched its all-in-one appliance for Next-Gen Sequencing (NGS) data processing, the GENALICE VAULT, at the annual conference of the American Society of Human Genetics.
About 5.7 million Americans have heart failure, half of whom will die from the disease within 5 years, according to the Centers for Disease Control and Prevention.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.
› Verified 2 days ago
Hector Samuel Lopez Vega, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2435 Blvd Luis A Ferre, Ponce, PR 00717 Phone: 787-901-4226 | |
Rosa Ines Fernandez, CRNA, MBA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3120 Calle Portugues, Villa Dos Rios, Ponce, PR 00730 Phone: 787-341-9680 |